Results from COMBI-AD led to FDA approval of the combination for the adjuvant treatment of patients with melanoma with BRAF ...

Already approved in melanoma, Novartis' Tafinlar and Mekinist ... had an effect in patients with BRAF V600E-mutation positive disease. Data presented at the American Society of Clinical Oncology ...

Jedd Wolchok, Stephen Hodi, and Antonio Ribas (from Memorial Sloan-Kettering, Dana-Farber Cancer Institute, and UCLA, respectively), will treat advanced melanoma patients who have a BRAF V600E ...

V600E is the most commonly encountered BRAF ... for unresectable or metastatic BRAF-positive melanoma and non-small cell lung cancer (NSCLC), and as a second-line therapy in combination with ...

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high ... were radiographically disease-free, BRAF V600E or V600K ctDNA was detected in 13% ...